CD274 and non-small cell lung carcinoma: Our meta-analysis revealed that in advanced NSCLC, irrespective of histological subtype (non-squamous or squamous), presence or absence of chemotherapy, high or low PD-L1 expression levels, and prior treatment history, the incidence of CIP was higher with ICI compared to chemotherapy for all grades and grades 3–5 adverse events in advanced NSCLC patients.